MAP1LC3A and Dravet syndrome: Specifically, our results showed that oxidative damage targets, among others, V0-ATPase, cathepsin D, and GFAP and this was coupled with a decreased LC3 II/I ratio early in the brain of individuals with DS and DS with AD [8,79].